Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia

Overview

The aim of this study was to determine if the addition of ketamine reduces remifentanil-induced hyperalgesia, improves its analgesic effect, inhibits IL(interleukin)-6 and IL-8 (inflammatory cytokines), and stimulates IL-10 (an anti-inflammatory cytokine).

Full Title of Study: “Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia Using Filaments, an Algometer, and Interleukins: a Double-blind, Randomized Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2012

Detailed Description

Opioids are very effective in pain relief, but they might lower pain threshold, making the patient more sensitive to a pain stimulus, a condition known as hyperalgesia [Angst; Clarck, 2006]. Opioid-induced hyperalgesia (OIH) is usually defined as a reduction in nociceptive thresholds in the peripheral field of the sensitized fibers [Koppert et al., 2003], and it is associated with increased pain and higher demand for postoperative analgesia [Guignard et al., 2000]. This phenomenon adversely impacts pain control, and has been suggested to occur in the peri-operative context, especially associated with the use of remifentanil, a short-acting opioid [Guignard et al., 2000]. Several mechanisms have been proposed to explain the hyperalgesia phenomenon, but the most important seems to be the activation of N-methyl-D-aspartate (NMDA) receptors [Célèrier et al., 2000]. Ketamine is a NMDA receptor antagonist that has been shown to reduce postoperative pain and the need for postoperative anesthetics and analgesics. Therefore, it is proposed that ketamine could prevent hyperalgesia, resulting in more effective and long-lasting postsurgical analgesia [Célèrier et al. 2000]. The results of studies of low dose of ketamine in the prevention of remifentanil-induced hyperalgesia are controversial. Joly et al. [2005] demonstrated a reduction in the consumption of opioids and in hyperalgesia assessed with monofilaments. However, Engelhardt et al [2008] showed no differences in pain scores or in postoperative opioid consumption. In addition, some authors observed higher levels of proinflammatory cytokines, associated with increased pain in mice receiving chronic opioid (morphine) infusion [Johnston et al., 2004; Liang et al., 2008]. Also, administration of proinflammatory cytokine inhibitors reduced phosphorylation of NMDA receptors [Zhang et al., 2008]. However, no study has examined the relationship between the use of remifentanil, the most frequently implicated opioid in OIH [Guignard et al., 2000], ketamine (drug capable of inhibiting NMDA-receptors and cytokines) [Dale et al., 2012], and the inflammatory response. The aim of this study was to determine if the addition of ketamine reduces remifentanil-induced hyperalgesia, improves its analgesic effect, inhibits IL-6 and IL-8 (inflammatory cytokines), and stimulates IL-10 (an anti-inflammatory cytokine) in patients submitted to laparoscopic cholecystectomy, a procedure with an usually neglected potential for postoperative pain and that has been poorly investigated in association with OIH.

Interventions

  • Drug: Ketamine
    • Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
  • Drug: Saline
    • Patients in group N (placebo) was administrated saline during surgery.

Arms, Groups and Cohorts

  • Active Comparator: Ketamine
    • A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), remifentanil (1 μg/kg), and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure. The patients in group ketamine received remifentanil (0.4 μg/kg/min) and ketamine (5 μg/kg/min). Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block.
  • Placebo Comparator: Saline
    • A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), 1 μg/kg remifentanil, and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure. The patients in group saline received remifentanil (0.4 μg/kg/min) and saline solution. Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block.

Clinical Trial Outcome Measures

Primary Measures

  • Pain 30 Minutes
    • Time Frame: 30 minutes
    • The scale measure pain after 30 minutes (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 60 Minutes
    • Time Frame: 60 minutes
    • The scale measure pain after 60 minutes (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 90 Minutes
    • Time Frame: 90 minutes
    • The scale measure pain after 90 minutes (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 120 Minutes
    • Time Frame: 120 minutes
    • The scale measure pain after 120 minutes (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 150 Minutes
    • Time Frame: 150 minutes
    • The scale measure pain after 150 minutes (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 180 Minutes
    • Time Frame: 180 minutes
    • The scale measure pain after 180 minutes (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 210 Minutes
    • Time Frame: 210 minutes
    • The scale measure pain after 210 minutes (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 240 Minutes
    • Time Frame: 240 minutes
    • The scale measure pain after 240 minutes (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 6 Hours
    • Time Frame: 6 hours
    • The scale measure pain after 6 hours (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 12 Hours
    • Time Frame: 12 hours
    • The scale measure pain after 12 hours (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 18 Hours
    • Time Frame: 18 hours
    • The scale measure pain after 18 hours (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.
  • Pain 24 Hours
    • Time Frame: 24 hours
    • The scale measure pain after 24 hours (0 – without pain and 10 worst pain possible). The individual can choose any number between 0 – 10.

Secondary Measures

  • Time to First Morphine Supplementation
    • Time Frame: 24 hours
  • Morphine Consumption Within 24 h
    • Time Frame: 24 hours
  • Hyperalgesia in the Preoperative Period as Measured With Monofilaments in Thenar Eminence
    • Time Frame: Before the procedure (Baseline)
    • The pain threshold was assessed using six von Frey monofilaments (0,05 g; 0,2 g; 2 g; 4 g; 10 g e 300 g) in thenar eminence in the preoperative period. The use of different von Frey monofilaments, starting with the lightest and ending with the heaviest, was separated by at least 30 seconds to reduce any anticipated responses due to a new stimulation that was performed too soon after the preceding stimulation. Three assessments were made for each monofilament, and this was considered positive when the patient responded to two of the determinations for each monofilament.
  • Hyperalgesia in the Postoperative Period as Measured With Monofilaments in Thenar Eminence
    • Time Frame: 24 hours after procedure
    • The pain threshold was assessed using six von Frey monofilaments (0,05 g; 0,2 g; 2 g; 4 g; 10 g e 300 g) in thenar eminence in the postoperative period (24 hours after procedure). The use of different von Frey monofilaments, starting with the lightest and ending with the heaviest, was separated by at least 30 seconds to reduce any anticipated responses due to a new stimulation that was performed too soon after the preceding stimulation. Three assessments were made for each monofilament, and this was considered positive when the patient responded to two of the determinations for each monofilament.
  • Hyperalgesia in the Preoperative Period as Measured With Monofilaments in the Periumbilical Region
    • Time Frame: Before the procedure (Baseline)
    • The pain threshold was assessed using six von Frey monofilaments (0,05 g; 0,2 g; 2 g; 4 g; 10 g e 300 g) in the periumbilical region in the preoperative period. The use of different von Frey monofilaments, starting with the lightest and ending with the heaviest, was separated by at least 30 seconds to reduce any anticipated responses due to a new stimulation that was performed too soon after the preceding stimulation. Three assessments were made for each monofilament, and this was considered positive when the patient responded to two of the determinations for each monofilament.
  • Hyperalgesia in the Postoperative Period as Measured With Monofilaments in the Periumbilical Region
    • Time Frame: 24h after the procedure
    • The pain threshold was assessed using six von Frey monofilaments (0,05 g; 0,2 g; 2 g; 4 g; 10 g e 300 g) in the periumbilical region in the postoperative period (24h after the procedure). The use of different von Frey monofilaments, starting with the lightest and ending with the heaviest, was separated by at least 30 seconds to reduce any anticipated responses due to a new stimulation that was performed too soon after the preceding stimulation. Three assessments were made for each monofilament, and this was considered positive when the patient responded to two of the determinations for each monofilament.
  • Hyperalgesia in the Preoperative Period as Measured With Algometer in Thenar Eminence
    • Time Frame: Baseline (before the procedure)
    • The mechanical pain threshold was evaluated using an algometer. The pressure was increased by 0.1 kgf/second until the patient complained of pain. The mean of three determinations was calculated.
  • Hyperalgesia in the Postoperative Period as Measured With Algometer in Thenar Eminence
    • Time Frame: 24 h after the procedure
    • The mechanical pain threshold was evaluated using an algometer. The pressure was increased by 0.1 kgf/second until the patient complained of pain. The mean of three determinations was calculated.
  • Hyperalgesia in the Preoperative Period as Measured With Algometer in the Periumbilical Region
    • Time Frame: Baseline (before the surgery)
    • The mechanical pain threshold was evaluated using an algometer. The pressure was increased by 0.1 kgf/second until the patient complained of pain. The mean of three determinations was calculated.
  • Hyperalgesia in the Postoperative Period as Measured With Algometer in the Periumbilical Region
    • Time Frame: 24 h after the procedure
    • The mechanical pain threshold was evaluated using an algometer. The pressure was increased by 0.1 kgf/second until the patient complained of pain. The mean of three determinations was calculated.
  • Extension of Hyperalgesia
    • Time Frame: 24 hours after the procedure
    • The 300-g filament was used 24 hours after the operation to induce a stimulus and delineate the extent of hyperalgesia from the periumbilical region. The stimulus was started outside the periumbilical region, where no pain sensation was reported, and continued every 0.5 cm until the 4 points of the periumbilical scar were reached (top, right side, left side, and bottom). The first point where the patient complained of pain was marked. If no pain sensation was reported, the stimulus was terminated 0.5 cm from the incision. The distance of each point from the surgical incision was measured, and the sum of the distances of the points was determined.
  • Allodynia as Detected With a Soft Brush in the Periumbilical Region Before the Procedure
    • Time Frame: Before the procedure (Baseline)
    • The evaluations using the soft brush were performed 2-3 cm from the incision in the periumbilical region (where the large trocar was placed) before the procedure
  • Allodynia as Detected With a Soft Brush in the Periumbilical Region 24 h After the Procedure
    • Time Frame: 24 h after the procedure
    • The evaluations using the soft brush were performed 2-3 cm from the incision in the periumbilical region (where the large trocar was placed) 24 h after the procedure
  • Allodynia as Detected With a Soft Brush in the Thenar Eminence Before the Procedure
    • Time Frame: Before the procedure (Baseline)
    • The evaluations using the soft brush were performed in the thenar eminence of the nondominant hand before the procedure
  • Allodynia as Detected With a Soft Brush in the Thenar Eminence 24 h After the Procedure
    • Time Frame: 24 h after the procedure
    • The evaluations using the soft brush were performed in the thenar eminence of the non dominant hand 24 h after the procedure
  • Serum Level of Interleukin (IL)-6 Before the Procedure
    • Time Frame: Baseline (Before the procedure)
    • Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes before the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-6 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology.
  • Serum Level of Interleukin (IL)-6 5 h After the Procedure
    • Time Frame: 5 h after the procedure
    • Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 5 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-6 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology.
  • Serum Level of Interleukin (IL)-6 24 h After the Procedure
    • Time Frame: 24 h after the procedure
    • Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 24 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-6 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology.
  • Serum Level of Interleukin (IL)-8 Before the Procedure
    • Time Frame: Baseline (Before the procedure)
    • Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes before the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-8 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology.
  • Serum Level of Interleukin (IL)-8 5 h After the Procedure
    • Time Frame: 5 h after the procedure
    • Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 5 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-8 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology.
  • Serum Level of Interleukin (IL)-8 24 h After the Procedure
    • Time Frame: 24 h after the procedure
    • Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 24 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-8 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology.
  • Serum Level of Interleukin (IL)-10 Before the Procedure
    • Time Frame: Baseline (Before the procedure)
    • Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes before the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-6 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology.
  • Serum Level of Interleukin (IL)-10 5h After the Procedure
    • Time Frame: 5h after the procedure
    • Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 5 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-10 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology.
  • Serum Level of Interleukin (IL)-10 24 h After the Procedure
    • Time Frame: 24 h after the procedure
    • Blood samples were drawn in ethylenediaminetetraacetic acid (EDTA) tubes 24 h after the surgery. The blood was centrifuged to separate the plasma and was stored at -70°C. IL-6 was analyzed using the enzyme-linked immunosorbent assay (ELISA) methodology.

Participating in This Clinical Trial

Inclusion Criteria

  • ≥ 18 years old – both sexes – ASA physical status I or II – undergoing laparoscopic cholecystectomy Exclusion Criteria:

  • chronic users of analgesics or had used opioids within 12 h of surgery – history of drug or alcohol abuse or psychiatric disorder – contraindications to self-administration of opioids (ie, unable to understand the patient-controlled analgesia [PCA] device) – contraindication for the use of ketamine, such as a psychiatric disorder, acute cardiovascular disorder, or unstable hypertension

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 78 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Federal University of São Paulo
  • Collaborator
    • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Provider of Information About this Clinical Study
    • Principal Investigator: Plínio da Cunha Leal, Master’s degree – Federal University of São Paulo
  • Overall Official(s)
    • Plínio da Cunha Leal, PhD, Principal Investigator, Federal University of São Paulo

References

Liang D, Shi X, Qiao Y, Angst MS, Yeomans DC, Clark JD. Chronic morphine administration enhances nociceptive sensitivity and local cytokine production after incision. Mol Pain. 2008 Feb 22;4:7. doi: 10.1186/1744-8069-4-7.

Zhang RX, Li A, Liu B, Wang L, Ren K, Zhang H, Berman BM, Lao L. IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats. Pain. 2008 Apr;135(3):232-239. doi: 10.1016/j.pain.2007.05.023. Epub 2007 Aug 6.

Dale O, Somogyi AA, Li Y, Sullivan T, Shavit Y. Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis. Anesth Analg. 2012 Oct;115(4):934-43. doi: 10.1213/ANE.0b013e3182662e30. Epub 2012 Jul 23.

Citations Reporting on Results

Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006 Mar;104(3):570-87. doi: 10.1097/00000542-200603000-00025.

Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schuttler J. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology. 2003 Jul;99(1):152-9. doi: 10.1097/00000542-200307000-00025.

Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P, Fletcher D, Chauvin M. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000 Aug;93(2):409-17. doi: 10.1097/00000542-200008000-00019.

Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, Simonnet G. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology. 2000 Feb;92(2):465-72. doi: 10.1097/00000542-200002000-00029.

Joly V, Richebe P, Guignard B, Fletcher D, Maurette P, Sessler DI, Chauvin M. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005 Jul;103(1):147-55. doi: 10.1097/00000542-200507000-00022.

Engelhardt T, Zaarour C, Naser B, Pehora C, de Ruiter J, Howard A, Crawford MW. Intraoperative low-dose ketamine does not prevent a remifentanil-induced increase in morphine requirement after pediatric scoliosis surgery. Anesth Analg. 2008 Oct;107(4):1170-5. doi: 10.1213/ane.0b013e318183919e.

Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, Langer S, Martin D, Green P, Fleshner M, Leinwand L, Maier SF, Watkins LR. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci. 2004 Aug 18;24(33):7353-65. doi: 10.1523/JNEUROSCI.1850-04.2004.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.